1. What is the term we use when we have treated patients aggressively for CVD risk factor reduction with current evidence-based recommendations, but they still have a vascular event?

2. List two diabetes medications that have reported a reduction in CVD outcomes from cardiovascular outcome trials in type 2 diabetes mellitus.

3. Dipeptidyl peptidase inhibitors (DPP-4 inhibitors) can be stated to be_______ for the risk of death, MI, and stroke in CVOT's to date.

4. Empagliflozin decreased which of the following outcomes?

5. Which of the following increases the risk of Acute Kidney Injury in patients using a SGLT2 inhibitor?

6. Which of the following reason(s) will pioglitazone be unlikely to be used for 1st line prevention of CVD?

« Return to Activity